Sort
10,766 grants matching “checkpoint inhibitor”
A multimodal approach to develop molecular markers to predict response to immune targeted agents in non-small cell lung cancer
$196,414Jeffrey C Thompson · University Of Pennsylvania · K08 · FY2020 · CA
A multimodal approach to develop molecular markers to predict response to immune targeted agents in non-small cell lung cancer
$196,414Jeffrey C Thompson · University Of Pennsylvania · K08 · FY2022 · CA
A multimodal approach to develop molecular markers to predict response to immune targeted agents in non-small cell lung cancer
$196,414Jeffrey C Thompson · University Of Pennsylvania · K08 · FY2019 · CA
A multimodal approach to develop molecular markers to predict response to immune targeted agents in non-small cell lung cancer
$196,414Jeffrey C Thompson · University Of Pennsylvania · K08 · FY2018 · CA
A multimodal approach to develop molecular markers to predict response to immune targeted agents in non-small cell lung cancer
$196,414Jeffrey C Thompson · University Of Pennsylvania · K08 · FY2021 · CA
Understanding how mitotic kinases drive EMT in breast cancers
$196,295Srikumar P Chellappan · H. Lee Moffitt Cancer Ctr & Res Inst · U54 · FY2017 · CA
Project 2: I CARE (Immunotherapy Cutaneous Adverse events REsearch)
$196,250Bao Q Vuong · City College Of New York · U54 · FY2024 · CA
Project 2: I CARE (Immunotherapy Cutaneous Adverse events REsearch)
$196,250Bao Q Vuong · City College Of New York · U54 · FY2025 · CA
Ménage à trois - Zika virus, DNA damage responses and microcephaly; is PNKP the molecular link?
$196,250Luis M. Schang · Cornell University · R21 · FY2019 · NS
Identification of the mechanism by which Toxoplasma activates the NLRP1 inflammasome
$196,250Jeroen Saeij · University Of California At Davis · R21 · FY2021 · AI
Deciphering the Immune Evasion Mechanisms in Mutant IDH1 Cancer
$196,029Meng-Ju Wu · Univ Of Massachusetts Med Sch Worcester · K22 · FY2025 · CA
Project 2: Transcriptional Dynamics and Temporal Reprogramming During Radiation Treatment
$195,828Jacob Gardinier Scott · Cleveland Clinic Lerner Com-Cwru · U54 · FY2022 · CA
E2F AND THE CONTROL OF APOPTOSIS
$195,677Ohio State University · R01 · FY2002 · CA
Improving decision-making in patients with resectable melanoma and pre-existing autoimmune disease considering immune checkpoint inhibition
$195,646Maria De Los Angeles Lopez-Olivo · University Of Tx Md Anderson Can Ctr · K08 · FY2024 · CA
Ras18-mediated Fanconi Anemia pathway activation in response to camptothecin
$195,500Komaraiah Palle · University Of South Alabama · R01 · FY2012 · GM
CYTOKINE SIGNALING PATHWAYS REGULATING A G1 CHECKPOINT
$195,419University Of Iowa · R01 · FY2001 · CA
Metabolic adaptation enables cisplatin resistance and inhibits tumor immunity
$195,369Vlad C Sandulache · University Of Tx Md Anderson Can Ctr · U54 · FY2025 · CA
B7-H3 in Medulloblastoma: evaluating its expression and function to harness new therapeutic targets
$195,184Allison M. Martin · Albert Einstein College Of Medicine · K08 · FY2023 · NS
B7-H3 in Medulloblastoma: evaluating its expression and function to harness new therapeutic targets
$195,184Allison M. Martin · Albert Einstein College Of Medicine · K08 · FY2024 · NS
Enhancing the TCR-induced Response of HLA-E-restricted Regulatory CD8 T Cells to Promote Allograft Tolerance
$195,126John Yongjoon Choi · Brigham And Women'S Hospital · K08 · FY2024 · AI
Role of persistent type I IFN signaling in immune suppression and tumorigenesis during chronic HIV infection
$195,000Scott G Kitchen · University Of California Los Angeles · R01 · FY2020 · CA
Enhancing the TCR-induced Response of HLA-E-restricted Regulatory CD8 T Cells to Promote Allograft Tolerance
$194,893John Yongjoon Choi · Brigham And Women'S Hospital · K08 · FY2025 · AI
BIOCHEMICAL BASIS FOR THERAPEUTIC ACTIVITY
$194,735University Of Texas Md Anderson Can Ctr · R01 · FY2000 · CA
Targeting Unique Meyloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer Mutations
$194,590Brian C Miller · Univ Of North Carolina Chapel Hill · K08 · FY2022 · CA
Targeting Unique Myeloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer Mutations
$194,590Brian C Miller · Harvard Medical School · K08 · FY2020 · CA